About: Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus
Creator	Dimopoulos, George Giamarellos-Bourboulis, Evangelos Akinosoglou, Karolina Damoulari, Christina Katrini, Konstantina Koufargyris, Panagiotis Lada, Malvina Psarrakis, Christos Renieris, Georgios Giamarellos-Bourboulis, E Kyriakopoulou, Μagdalini
Source	Medline; PMC; WHO
abstract	BACKGROUND: The pneumonia of COVID-19 illness has often a subtle initial presentation making mandatory the use of biomarkers for evaluation of severity and prediction of final patient disposition. We evaluated the use of hydrogen sulfide (H2S) for the outcome of COVID-19 pneumonia. MATERIALS & METHODS: We studied 74 patients with COVID-19. Clinical data were collected, and survival predictors were calculated. Blood was collected within 24 hours after admission (day 1) and on day 7. H2S was measured in sera by monobromobimane derivation (MBB) followed by high performance liquid chromatography and correlated to other markers like procalcitonin (PCT) and C- reactive protein (CRP). Tumor necrosis factor alpha (TNFα) and interleukin (IL)-6 were also measured in serum. RESULTS: Survivors had significantly higher H2S levels on day 1 and 7 after admission. A cut-off point of 150.44 μM could discriminate survivors from non-survivors with 80% sensitivity, 73.4% specificity and negative predictive value 95.9%. Mortality after 28 days was 32% with admission levels lower or equal to 150.44 μΜ and 4.1% with levels above 150.44 μΜ (p: 0.0008). Mortality was significantly greater among patients with a decrease of H2S levels from day 1 to day 7 greater or equal to 36% (p: 0.0005). Serum H2S on day 1 was negatively correlated with IL- 6 and CRP and positively correlated with the absolute lymphocyte count in peripheral blood. CONCLUSION: It is concluded that H2S is a potential marker for severity and final outcome of pneumonia by the SARS-CoV-2 coronavirus. Its correlation with IL- 6 suggests anti-inflammatory properties.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1097/shk.0000000000001562
bibo:pmid	32433216
has license	no-cc
sha1sum (hex)	e3e4048bf26b624343c5c20741f427183532b1ff
schema:url	https://doi.org/10.1097/shk.0000000000001562
resource representing a document's title	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus
has PubMed Central identifier	PMC7363385
has PubMed identifier	32433216
schema:publication	Shock
resource representing a document's body	covid:e3e4048bf26b624343c5c20741f427183532b1ff#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'illness' named entity 'pneumonia' named entity 'pneumonia' named entity 'COVID-19' named entity 'hydrogen sulfide' named entity 'pneumonia' named entity 'CORONA VIRUS' named entity 'SERUM' named entity 'serum' named entity 'H2S' named entity 'endogenous' named entity 'lung' named entity 'COVID' named entity 'Serum' named entity '28 days' named entity 'independent variable' named entity 'pathogenesis' named entity 'lung' named entity 'endothelial dysfunction' named entity 'H2S' named entity 'H2S' named entity 'coronavirus' named entity 'detection limit' named entity 'H2S' named entity 'ischemia-reperfusion injury' named entity 'H2S' named entity 'sulfosalicylic acid' named entity 'negatively correlated' named entity 'epithelia' named entity 'H2S' named entity 'H2S' named entity 'pro-inflammatory' named entity 'follow-up' named entity 'H2S' named entity 'lung' named entity 'COVID' named entity 'pyrogen' named entity 'APACHE II' named entity 'therapeutic strategies' named entity 'mice' named entity 'Berlin' named entity 'Hennigsdorf' named entity 'study endpoint' named entity 'serum' named entity 'CRP' named entity 'H2S' named entity 'Odds ratios' named entity 'SARS-CoV-2' named entity 'clinical study' named entity 'IL-6' named entity 'absolute neutrophil count' named entity 'Serum concentrations' named entity 'H2S' named entity 'Physiology' named entity 'serum' named entity 'SARS-CoV-2' named entity 'disodium phosphate' named entity 'monobromobimane' named entity 'lymphocyte count' named entity 'H2S' named entity 'd-dimers' named entity 'serum levels' named entity 'H2S' named entity 'March 2020' named entity 'enzyme immunoassay' named entity 'H2S' named entity 'endotoxemia' named entity 'novel-coronavirus' named entity 'cytokine storm'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software